Bright Minds Biosciences DRUG 深 沪
已收盘 01-09 16:00:00 美东时间
86.75
-3.260
-3.62%
华盛通- 最 高92.735
- 今 开90.12
- 成交量 18.22万股
- 最 低 85.645
- 昨 收 90.01
- 总市值 6.76亿
- 52周最高 123.75
- 市盈率 静 --
- 换手率 2.34%
- 52周最低 23.175
- 委 比 17.65%
- 总股本 778.72万
- 历史最高 123.75
- 量 比 0.29
- 振 幅 7.88%
- 历史最低 0.93
- 每 手 1
- 风险率 17.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bright Minds prices $175M stock offering
Bright Minds Biosciences (DRUG) priced its previously announced public offering of ~1.95M shares at a price of $90.00 per share. Gross proceeds are expected to be ~$175M. The underwriters have a 30-da...
01-08 15:29
SanDisk To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-07 21:04
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Bright Minds Biosciences Announces Launch Of $100M Public Offering
-- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the launch of a public offering of common shares in the capital of the Company (the "Common Shares") and, in lieu of
01-07 05:01
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday
Bright Minds' stock rose after its epilepsy drug cut seizures in a Phase 2 trial, showed good safety, and improved sleep, setting up plans for larger global studies.
01-07 00:52
美股大行评级 | 潜在涨幅1391.05%！Maison Solutions获Ascendiant Capital升目标价至4.5美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4.25美元升至4.5美元；HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从39美元升至50美元
2025-12-31 10:25
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $115 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $115 price target.
2025-12-30 23:40
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
Bright Minds Biosciences will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the 2025 American Epilepsy Society Annual Meeting on December 7, 2025. The company focuses on developing selective 5-HT2 agonists for treating epilepsy, depression, and CNS disorders, with a unique platform of serotonergic agonists.
2025-11-25 21:30
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences has added four global experts in Prader-Willi Syndrome (PWS) to its Scientific Advisory Board to support its new PWS program. The company has initiated a clinical program focusing on BMB-101, a novel drug candidate aimed at addressing hyperphagia and behavioral symptoms of PWS. The program includes the NOVA clinical study, a Phase 2a trial designed to assess BMB-101's efficacy and safety. The experts' expertise will be in...
2025-11-17 11:50
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Bright Minds Biosciences announced the launch of its Prader-Willi Syndrome (PWS) program, including a Phase 2a NOVA study to evaluate BMB-101 for treating PWS symptoms and a Phase 1 study for BMB-105. The Company will hold a webcast on November 6 featuring experts discussing PWS treatment needs and clinical assessments. CEO Ian McDonald emphasized the potential of 5-HT₂C agonists to address PWS's underlying issues. BMB-101 has shown good safety a...
2025-11-06 11:30
